vs
Side-by-side financial comparison of ADMA BIOLOGICS, INC. (ADMA) and ServisFirst Bancshares, Inc. (SFBS). Click either name above to swap in a different company.
ServisFirst Bancshares, Inc. is the larger business by last-quarter revenue ($159.0M vs $139.2M, roughly 1.1× ADMA BIOLOGICS, INC.). ServisFirst Bancshares, Inc. runs the higher net margin — 52.2% vs 35.5%, a 16.7% gap on every dollar of revenue. Over the past eight quarters, ADMA BIOLOGICS, INC.'s revenue compounded faster (30.4% CAGR vs 17.7%).
ADMA Biologics Inc. is a biopharmaceutical enterprise focused on the research, development, manufacturing and commercialization of specialty plasma-derived immunoglobulin therapies. It primarily operates in the United States, catering to patients with primary immunodeficiency and other immune-related disorders, healthcare providers and medical institutions across its core immune health therapeutic segment.
ServisFirst Bancshares, Inc. is a U.S.-based bank holding company operating full-service banking locations primarily across the Southeastern United States. It offers a full suite of commercial banking, consumer banking, wealth management, and mortgage lending services to small and medium-sized businesses, professional clients, and individual consumers.
ADMA vs SFBS — Head-to-Head
Income Statement — Q4 FY2025 vs Q1 FY2026
| Metric | | |
|---|---|---|
| Revenue | $139.2M | $159.0M |
| Net Profit | $49.4M | $83.0M |
| Gross Margin | 63.8% | — |
| Operating Margin | 45.1% | — |
| Net Margin | 35.5% | 52.2% |
| Revenue YoY | 18.4% | — |
| Net Profit YoY | -55.9% | 31.2% |
| EPS (diluted) | $0.20 | $1.52 |
Green = leading value per metric. Periods may differ when fiscal calendars don't align.
8-Quarter Revenue & Profit Trend
Side-by-side quarterly history. Quarters aligned by calendar period so offset fiscal years line up.
| Q1 26 | — | $159.0M | ||
| Q4 25 | $139.2M | $162.2M | ||
| Q3 25 | $134.2M | $136.3M | ||
| Q2 25 | $122.0M | $132.1M | ||
| Q1 25 | $114.8M | $131.8M | ||
| Q4 24 | $117.5M | $131.9M | ||
| Q3 24 | $119.8M | $123.7M | ||
| Q2 24 | $107.2M | $114.8M |
| Q1 26 | — | $83.0M | ||
| Q4 25 | $49.4M | $86.4M | ||
| Q3 25 | $36.4M | $65.6M | ||
| Q2 25 | $34.2M | $61.4M | ||
| Q1 25 | $26.9M | $63.2M | ||
| Q4 24 | $111.9M | $65.2M | ||
| Q3 24 | $35.9M | $59.9M | ||
| Q2 24 | $32.1M | $52.1M |
| Q1 26 | — | — | ||
| Q4 25 | 63.8% | — | ||
| Q3 25 | 56.3% | — | ||
| Q2 25 | 55.1% | — | ||
| Q1 25 | 53.2% | — | ||
| Q4 24 | 53.9% | — | ||
| Q3 24 | 49.8% | — | ||
| Q2 24 | 53.6% | — |
| Q1 26 | — | — | ||
| Q4 25 | 45.1% | 66.3% | ||
| Q3 25 | 38.0% | 57.8% | ||
| Q2 25 | 35.1% | 58.0% | ||
| Q1 25 | 30.4% | 60.0% | ||
| Q4 24 | 32.6% | 60.2% | ||
| Q3 24 | 33.1% | 58.5% | ||
| Q2 24 | 36.6% | 58.0% |
| Q1 26 | — | 52.2% | ||
| Q4 25 | 35.5% | 59.0% | ||
| Q3 25 | 27.1% | 48.1% | ||
| Q2 25 | 28.1% | 46.5% | ||
| Q1 25 | 23.4% | 48.0% | ||
| Q4 24 | 95.2% | 52.9% | ||
| Q3 24 | 30.0% | 48.4% | ||
| Q2 24 | 29.9% | 45.4% |
| Q1 26 | — | $1.52 | ||
| Q4 25 | $0.20 | $1.58 | ||
| Q3 25 | $0.15 | $1.20 | ||
| Q2 25 | $0.14 | $1.12 | ||
| Q1 25 | $0.11 | $1.16 | ||
| Q4 24 | $0.45 | $1.19 | ||
| Q3 24 | $0.15 | $1.10 | ||
| Q2 24 | $0.13 | $0.95 |
Balance Sheet & Financial Strength
Snapshot of each company's liquidity, leverage and book value from the latest quarter.
| Metric | | |
|---|---|---|
| Cash + ST InvestmentsLiquidity on hand | $87.6M | $1.8B |
| Total DebtLower is stronger | $72.1M | — |
| Stockholders' EquityBook value | $477.3M | $1.9B |
| Total Assets | $624.2M | $18.2B |
| Debt / EquityLower = less leverage | 0.15× | — |
8-quarter trend — quarters aligned by calendar period.
| Q1 26 | — | $1.8B | ||
| Q4 25 | $87.6M | — | ||
| Q3 25 | $61.4M | — | ||
| Q2 25 | $90.3M | — | ||
| Q1 25 | $71.6M | — | ||
| Q4 24 | $103.1M | — | ||
| Q3 24 | $86.7M | — | ||
| Q2 24 | $88.2M | — |
| Q1 26 | — | — | ||
| Q4 25 | $72.1M | — | ||
| Q3 25 | $72.4M | — | ||
| Q2 25 | — | — | ||
| Q1 25 | — | — | ||
| Q4 24 | $72.3M | — | ||
| Q3 24 | — | — | ||
| Q2 24 | — | — |
| Q1 26 | — | $1.9B | ||
| Q4 25 | $477.3M | $1.8B | ||
| Q3 25 | $431.2M | $1.8B | ||
| Q2 25 | $398.3M | $1.7B | ||
| Q1 25 | $373.4M | $1.7B | ||
| Q4 24 | $349.0M | $1.6B | ||
| Q3 24 | $231.9M | $1.6B | ||
| Q2 24 | $188.3M | $1.5B |
| Q1 26 | — | $18.2B | ||
| Q4 25 | $624.2M | $17.7B | ||
| Q3 25 | $568.7M | $17.6B | ||
| Q2 25 | $558.4M | $17.4B | ||
| Q1 25 | $510.6M | $18.6B | ||
| Q4 24 | $488.7M | $17.4B | ||
| Q3 24 | $390.6M | $16.4B | ||
| Q2 24 | $376.4M | $16.0B |
| Q1 26 | — | — | ||
| Q4 25 | 0.15× | — | ||
| Q3 25 | 0.17× | — | ||
| Q2 25 | — | — | ||
| Q1 25 | — | — | ||
| Q4 24 | 0.21× | — | ||
| Q3 24 | — | — | ||
| Q2 24 | — | — |
Cash Flow & Capital Efficiency
How much cash each business actually produces after reinvestment. Cash flow is harder to manipulate than net income.
| Metric | | |
|---|---|---|
| Operating Cash FlowLast quarter | $35.6M | — |
| Free Cash FlowOCF − Capex | $34.6M | — |
| FCF MarginFCF / Revenue | 24.8% | — |
| Capex IntensityCapex / Revenue | 0.8% | — |
| Cash ConversionOCF / Net Profit | 0.72× | — |
| TTM Free Cash FlowTrailing 4 quarters | $27.8M | — |
8-quarter trend — quarters aligned by calendar period.
| Q1 26 | — | — | ||
| Q4 25 | $35.6M | $355.2M | ||
| Q3 25 | $13.3M | $140.9M | ||
| Q2 25 | $21.1M | $67.6M | ||
| Q1 25 | $-19.7M | $48.0M | ||
| Q4 24 | $50.2M | $252.9M | ||
| Q3 24 | $25.0M | $84.0M | ||
| Q2 24 | $45.6M | $48.3M |
| Q1 26 | — | — | ||
| Q4 25 | $34.6M | — | ||
| Q3 25 | $-1.1M | — | ||
| Q2 25 | $18.7M | — | ||
| Q1 25 | $-24.4M | — | ||
| Q4 24 | $47.5M | — | ||
| Q3 24 | $24.0M | — | ||
| Q2 24 | $43.6M | — |
| Q1 26 | — | — | ||
| Q4 25 | 24.8% | — | ||
| Q3 25 | -0.8% | — | ||
| Q2 25 | 15.3% | — | ||
| Q1 25 | -21.2% | — | ||
| Q4 24 | 40.4% | — | ||
| Q3 24 | 20.0% | — | ||
| Q2 24 | 40.7% | — |
| Q1 26 | — | — | ||
| Q4 25 | 0.8% | — | ||
| Q3 25 | 10.7% | — | ||
| Q2 25 | 2.0% | — | ||
| Q1 25 | 4.1% | — | ||
| Q4 24 | 2.3% | — | ||
| Q3 24 | 0.9% | — | ||
| Q2 24 | 1.9% | — |
| Q1 26 | — | — | ||
| Q4 25 | 0.72× | 4.11× | ||
| Q3 25 | 0.36× | 2.15× | ||
| Q2 25 | 0.62× | 1.10× | ||
| Q1 25 | -0.73× | 0.76× | ||
| Q4 24 | 0.45× | 3.88× | ||
| Q3 24 | 0.70× | 1.40× | ||
| Q2 24 | 1.42× | 0.93× |
Financial Flow Comparison
Revenue → gross profit → operating profit → net profit for each company.
Revenue Breakdown by Segment
ADMA
| ADMA Bio Manufacturing Segment | $123.1M | 88% |
| Other | $16.0M | 12% |
SFBS
| Net Interest Income | $148.1M | 93% |
| Noninterest Income | $10.8M | 7% |
